RxDoctor Payments Data

Alfonso Arevalo, DO

Orthopaedic Surgery · Wilmington, DENPI 1669912028

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (39.4%), education and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Smith+Nephew at 46.5% of the total. Reporting peaked in 2023 at $11,018 and has fallen 83.3% since, to $1,845 in 2025.

$18,285in general payments, 2019–2025

Across 118 payments — averaging $154.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$9K
  • Stryker$3K
  • Liberty Surgical Inc.$3K
  • Arthrex$2K
  • Eclipse Technology Solutions Inc.$1K
  • Prodigy Surgical Distribution, Inc.$478
  • plus $128 from 7 others

What the payments were for

  • Travel & lodging$7,20439%
  • Food & beverage$3,88121%
  • Education$7,20039%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,285 in reported general payments places this provider in the 75th percentile of 70 orthopaedic surgery providers in Delaware.

See all orthopaedic surgery providers in Delaware

Medicare billing

Part B allowed, 2024
$107,091
Medicare patients
250
Services billed
2,021

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Meloxicam22$98

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →